In this paper, we will be focusing on medicinal products (medicines, including biologics and vaccines), though many of these principles can be applied to medical devices.
Read moreIncreasing manufacturing capacity for COVID-19 vaccines is one of the biggest challenges we need to address in our common goal to bring this pandemic to an end. Science has delivered not one but several vaccines that are safe and effective and the goal is ensure fair and equitable delivery to vaccines to those who most...
Read more2020 witnessed a decade of scientific progress compressed into just 12 months. And as a result we now have, ahead of all predictions, a number of C-19 vaccines that can protect the heroic healthcare workers, the elderly and the vulnerable; and hopefully society as a whole as long as we can keep the mutations in...
Read moreThis blog was originally published on Media Planet Infectious Disease campaign on 24 March 2021. Whilst we are still in the midst of COVID-19, the worst pandemic since 1918 which is affecting every part of our lives, we can draw some lessons that will allow us to be better prepared for the future. The first...
Read moreA summit was convened in a matter of weeks by Chatham House, in collaboration with COVAX, IFPMA, DCVMN, and BIO, took place on 8-9 March 2021. A discussion document helped inform participants, gave an overview of the current COVID-19 vaccine manufacturing supply chain and identified emerging challenges. While the meeting was conducted under Chatham House rule to facilitate an...
Read moreThis virtual press briefing was a readout of the recommendations to address manufacturing challenges.
Read more9 March 2021: Chatham House, in collaboration with COVAX, IFPMA, DVCMN, and BIO, convened a Global COVID-19 Vaccine Supply Chain & Manufacturing Summit on 8th and 9th March. The unprecedented scaling up of vaccine manufacturing, from zero to billions of doses in record time, has led to shortages that are impacting the entire vaccine supply chain....
Read moreAntibiotics have transformed healthcare. But today, the ubiquitous use of these live-saving drugs has led to the development of antibiotic-resistant bacteria. Once-treatable diseases like common infections of the bloodstream, urinary or respiratory tracts are becoming more difficult to treat using these tools. Combating drug resistance means facing a silent pandemic that could dwarf the impact...
Read moreThis blog was originally posted on Pharma Boardroom on 23 February 2021 The story of COVID-19 vaccines is one of incredible collaboration. Never before has there been such an effort on a mass scale to solve a global health crisis. We’ve seen a decade of normal vaccine development compressed into just ten months. From the...
Read moreThe AMR Action Fund, launched in July 2020, aims to bring 2 to 4 new antibiotics to patients by the end of the decade and facilitate needed long-term solutions FEBRUARY 18, 2021, BOSTON — Today, the AMR Action Fund announced its first initial close with non-pharmaceutical industry investments of more than US$140 million from the...
Read more